K K Venkatesh1, V M Castro2, R H Perlis2,3,4, A J Kaimal5. 1. Department of Obstetrics and Gynecology, Massachusetts General Hospital and Brigham and Women's Hospital Boston, MA, USA. 2. Department of Psychiatry, Center for Experimental Drugs and Diagnostics, Massachusetts General Hospital Boston, MA, USA. 3. Center for Human Genetic Research, Massachusetts General Hospital Boston, MA, USA. 4. Harvard Medical School, Boston, MA, USA. 5. Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, USA.
Abstract
OBJECTIVE: To examine the impact of pharmacologic treatment for depression on obstetric outcomes in women treated for depression during the 2 years prior to pregnancy. STUDY DESIGN: Observational cohort study among 2859 women treated for depression during the 2 years prior to pregnancy. The primary exposure was any antidepressant treatment during pregnancy. Secondary analyses examined the impact of treatment by period of antidepressant exposure. Multivariable logistic regression models as well as propensity score analysis was utilized. RESULTS: Among 2859 women, 1648 (58%) were treated with antidepressant medication during pregnancy. Women who received antidepressants had no difference in preterm and early-term deliveries, Apgar scores, and small for gestational age (SGA); they had a lower likelihood of breastfeeding (adjusted odds ratio (AOR) 0.69, (95% confidence interval (CI): 0.51 to 0.94)). In secondary analysis, women who used antidepressants all three trimesters who delivered at term were more likely to deliver early term (AOR 1.36, (95% CI: 1.09 to 1.72)). Women who were treated with antidepressants only during the first and second trimesters had a reduced likelihood of SGA (AOR: 0.51 (95% CI: 0.32 to 0.83)). Generally similar results were observed with propensity score analysis. CONCLUSION: Antidepressant exposure during pregnancy does not confer an increased risk of preterm birth nor growth restriction in women recently treated for depression, but also does not appear to markedly improve these outcomes.
OBJECTIVE: To examine the impact of pharmacologic treatment for depression on obstetric outcomes in women treated for depression during the 2 years prior to pregnancy. STUDY DESIGN: Observational cohort study among 2859 women treated for depression during the 2 years prior to pregnancy. The primary exposure was any antidepressant treatment during pregnancy. Secondary analyses examined the impact of treatment by period of antidepressant exposure. Multivariable logistic regression models as well as propensity score analysis was utilized. RESULTS: Among 2859 women, 1648 (58%) were treated with antidepressant medication during pregnancy. Women who received antidepressants had no difference in preterm and early-term deliveries, Apgar scores, and small for gestational age (SGA); they had a lower likelihood of breastfeeding (adjusted odds ratio (AOR) 0.69, (95% confidence interval (CI): 0.51 to 0.94)). In secondary analysis, women who used antidepressants all three trimesters who delivered at term were more likely to deliver early term (AOR 1.36, (95% CI: 1.09 to 1.72)). Women who were treated with antidepressants only during the first and second trimesters had a reduced likelihood of SGA (AOR: 0.51 (95% CI: 0.32 to 0.83)). Generally similar results were observed with propensity score analysis. CONCLUSION: Antidepressant exposure during pregnancy does not confer an increased risk of preterm birth nor growth restriction in women recently treated for depression, but also does not appear to markedly improve these outcomes.
Authors: Tim F Oberlander; Shaila Misri; Colleen E Fitzgerald; Xanthoula Kostaras; Dan Rurak; Wayne Riggs Journal: J Clin Psychiatry Date: 2004-02 Impact factor: 4.384
Authors: Kimberly H Pearson; Ruta M Nonacs; Adele C Viguera; Vicki L Heller; Laura F Petrillo; Mina Brandes; John Hennen; Lee S Cohen Journal: J Clin Psychiatry Date: 2007-08 Impact factor: 4.384
Authors: Paige D Wartko; Noel S Weiss; Daniel A Enquobahrie; K C Gary Chan; Alyssa Stephenson-Famy; Beth A Mueller; Sascha Dublin Journal: J Clin Psychopharmacol Date: 2021 Jul-Aug 01 Impact factor: 3.153